Search

everythinglearnresearchcommunity

for

Search:↓

Polycystic Ovary Syndrome (PCOS) is a common condition in women that can cause metabolic, reproductive, and psychological issues, and requires lifestyle changes and medication for management.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

The European Society of Endocrinology advises individualized long-term management for PCOS, focusing on lifestyle changes, accurate diagnosis, and treatments for associated health risks and symptoms.

Chemicals and body size might change when puberty starts and progresses, but more research is needed to confirm this.

The document concludes that insulin resistance is key in PCOS development and early treatment is crucial to prevent complications.

Early diagnosis and individualized treatment improve outcomes for Congenital Adrenal Hyperplasia.

Hormone therapy is essential for transgender individuals but requires careful management due to possible metabolic effects.

Skin changes can help diagnose and manage endocrine disorders like thyroid problems, diabetes, and adrenal gland conditions.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

Dermal Papilla cells are a promising tool for evaluating hair growth treatments.

Women with PCOS often have skin problems like excessive hair, acne, hair loss, and dark patches, which can be treated with hormonal and non-hormonal therapies.

The conclusion is that published guidelines are improving transgender medical care, but more research and education in transgender medicine are needed.

The conclusion is that the best initial treatment for hirsutism is usually oral contraceptives, with the addition of antiandrogens or insulin sensitizers if needed, and topical eflornithine or laser treatments as supplementary options.

Oxidative stress is a key factor in the development of Polycystic Ovary Syndrome, and weight management can improve symptoms.

SHBG may be a useful early indicator and treatment target for PCOS.

Menopause and aging can affect women's quality of life and sexuality, but hormone therapies may help alleviate these issues.

AMH helps estimate ovarian reserve but doesn't predict pregnancy chances; age is more important.

Prolactin may play a significant role in skin and hair health and could be a target for treating skin and hair disorders.

Eating healthy, exercising, and taking certain supplements can help manage Polycystic Ovary Syndrome symptoms.

The document concludes with guidance for doctors on diagnosing and treating hirsutism effectively and safely.

Hidradenitis suppurativa may be related to hormones and patients often have metabolic disorders; more research is needed to understand this connection.

The conclusion is that hirsutism should be diagnosed and treated because it affects quality of life and may signal other health problems.

PFS and PSSD are similar conditions with persistent sexual dysfunction after stopping medication.

Finasteride effectively reduces hair growth in women with polycystic ovary syndrome or idiopathic hirsutism.

Blocking the prolactin receptor might help treat various diseases, but more research is needed.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.

A team approach is crucial for managing PCOS, with dermatologists playing a key role.

The document concludes that new treatments are needed to better manage acne and reduce side effects related to current therapies.